CDKN2A and glioblastoma: Methylated MGMT status is recognized as the most robust predictive marker in patients with GBM; however, there is insufficient evidence regarding the impact of CDKN2A homozygous deletion on OS for IDH‐wildtype GBM, and therefore, its prognostic impact remains controversial.20